EU Clears Abbott Purchase of Solvay Pharmaceuticals

Feb. 11, 2010
Deal is contingent on the divestment of the cystic fibrosis testing business of Solvay subsidiary Innogenetics

European regulators on Thursday cleared Belgian chemical company Solvay's plans to sell its entire pharmaceutical business to U.S. pharmaceutical firm Abbott for more than 4.5 billion euros.

The European Commission's approval for the deal, whose worth could rise to 5.2 billion euros (US$7.1 billion) if add-on clauses are met, is "conditional upon the divestment of the cystic fibrosis testing business of Solvay Pharma's subsidiary Innogenetics," a statement said.

The sale sees Abbott take over all Solvay's pharmaceuticals employees and assume liabilities including future exposure to litigation.

Solvay said in September it would invest the proceeds in its original chemicals and plastics business, focusing on geographical expansion and attention to new products with a "low carbon footprint."

A round of consolidation has taken place throughout the pharmaceutical industry since Pfizer, already the world's biggest pharmaceutical firm, announced a $68 billion takeover of Wyeth in January.

That was followed by U.S. giants Merck agreeing to buy rival Schering-Plough for $41.1 billion in March.

Copyright Agence France-Presse, 2010

About the Author

Agence France-Presse

Copyright Agence France-Presse, 2002-2024. AFP text, photos, graphics and logos shall not be reproduced, published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP shall not be held liable for any delays, inaccuracies, errors or omissions in any AFP content, or for any actions taken in consequence.

Sponsored Recommendations

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!